Sonnet BioTherapeutics (SONN) announced that Pankaj Mohan, PhD, Chief Executive Officer of Sonnet, and John Cini, PhD, Chief Scientific Officer of Sonnet, participated in a Virtual Investor “What this Means” segment released by Sonnet. As part of the segment, Drs. Mohan and Cini discussed the recent U.S. Patent titled, “Interleukin 18 Variants and Fusion Proteins Comprising Same,” covering two of its novel drug candidates, SON-1411 and SON-1400, each containing a modified version of recombinant human interleukin-18.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SONN:
- Sonnet BioTherapeutics prices $5M at-the-market offering
- Sonnet BioTherapeutics Secures Patent for Cancer Drugs
- Sonnet BioTherapeutics announces USPTO issued U.S. patent on IL-18
- Sonnet BioTherapeutics files to sell common stock, warrants, no amount given
- Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance